Global Lupus Therapeutic Market, by Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Biologics, Antimalarial Drugs, Corticosteroids, and Others {Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others}), by Route of Administration (Oral, Subcutaneous, Intravenous, and Others {Intramuscular, Intradermal, among others}, by End User (Hospitals & Clinics, Diagnostic Laboratories, and Others {Homecare, Specialty Centre, among others}), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2,795.2 million in 2022 and is expected to exhibit a CAGR of 8.6% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Key players operating in the market are focusing on receiving product approvals from regulatory authorities and this is expected to drive the global lupus therapeutic market growth over the forecast period.
For instance, in September 2019, F. Hoffmann-La Roche Ltd, a Switzerland-based pharmaceutical company announced that it received the Breakthrough Therapy Designation (a process designed to expedite the development and review of drugs that are intended to treat a serious health condition) from U.S. Food and Drug Administration (FDA) for its drug Gazyva (obinutuzumab) which is indicated for the treatment of lupus nephritis (caused due to Systemic Lupus Erythematosus) in adults.
Global Lupus Therapeutic Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 409 million cases and 5.8 million deaths due to Coronavirus (COVID-19) were reported up till February 13, 2022, across the globe.
The COVID-19 pandemic has affected several markets across the globe, however, it is expected to have a positive effect on the global lupus therapeutic market, owing to possible association between lupus and COVID-19. For instance, according to an article by published by Cells journal, an open access scientific journal of cell biology, molecular biology, and biophysics in December 2021, there is growing scientific evidence that SARS-CoV2 can lead to a disruption of the immune system of the human body by causing autoimmune diseases such as rheumatic arthritis, inflammatory myopathies, systemic lupus erythematosus (SLE), and others.
Browse 49 Market Data Tables and 37 Figures spread through 167 Pages and in-depth TOC on “Lupus Therapeutic Market”- Global Forecast to 2030, by Disease Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, and Neonatal Lupus), by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Biologics, Antimalarial Drugs, Corticosteroids, and Others {Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others}), by Route of Administration (Oral, Subcutaneous, Intravenous, and Others {Intramuscular, Intradermal, among others}, by End User (Hospitals & Clinics, Diagnostic Laboratories, and Others {Homecare, Specialty Centre, among others}), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the global lupus therapeutic market, click the link below:
https://www.coherentmarketinsights.com/market-insight/lupus-therapeutic-market-4958
Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations and acquisitions, in order to strengthen their position in the market. For instance, in November 2020, iSD Immunotech, a Denmark0based biotechnology company announced that it has entered into a collaboration with Biogen, a U.S. based biotechnology company for development of a drug candidate to be used in the treatment of autoimmune disease lupus.
Key Takeaways of the Global Lupus Therapeutic Market:
- The global lupus therapeutic market is expected to exhibit a CAGR of 8.6% over the forecast period, owing to growing clinical research in development of lupus therapeutics. For instance, in January 2022, Vera Therapeutics, a U.S. based clinical-stage biotechnology company focused on developing treatments for immunological diseases such as lupus, announced that it has initiated Phase III clinical trials for its drug candidate Atacicept, indicated to treat Lupus Nephritis in adults.
- Among disease type, Systemic Lupus Erythematosus (SLE) segment is expected to account for the largest market share in 2022, owing to market players focusing on getting regulatory approvals and launching drugs used for treatment of lupus. For instance, in January 2021, Aurinia Pharmaceuticals Inc., a Canada-based biopharmaceutical company announced that it has received the U.S. Food and Drug Administration approval for its drug Lupkynis (voclosporin), indicated to be used in the treatment of lupus nephritis, kidney inflammation caused by systemic lupus erythematosus (SLE).
- Key players operating in the global lupus therapeutic market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
